FDA Considers Approving CRISPR Gene-Editing Therapy for Sickle Cell Disease by Dec. 8

The FDA is considering approving the first therapy based on CRISPR gene-editing technology, which could be life-changing for people with sickle cell disease. The therapy has been reviewed by an expert panel and the FDA must make a decision by December 8. This would be the first genome editing approved by the FDA and is seen as a significant milestone in medical progress.